Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5604_Библиотеки_им_академика_М_И_Перельмана.pdf
Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future … 115
Tabl e 5 Applications of CNOs in biomedical field. Adapted and reproduced with permission from
MDPI [114]
Name of CNOs Application Comments
f-CNO reinforced zein
hydrogels
f-CNO-polycaprolactone Anticancer
p-CNO-glassy carbon
electrode
f-CNO-gelatin hydrogel Anticancer
Ox-CNO/Chitosan/Polyvinyl
alcohol
p-CNO, Ox-CNO,
Fluorescent CNO
Anticancer
drug
delivery
drug
delivery
DNA sensor Large surface area and fast electron transfer are
drug
delivery
Tissue
engineering
Cell
imaging
Exhibit pH-responsive sustained drug release
spanning over 15 days, Enhanced mechanical
strength, improved cytocompatibility
pH-dependent drug release, improved
biocompatibility, mechanical strength, and
hydrophobicity
the reasons behind sensing biomolecular
interaction
Sustained release of 5-FU drug over 15 days and
improved tensile strength indicating the prospect
in tissue engineering and drug delivery
Exhibit negative allergic response, tissue
regeneration capability
As an alternative to organic dyes, it can provide
high resolution cellular image, Exhibited
improved stability and cytocompatibility
3.6 Nanohorns in Drug Delivery
Although Carbon nanohorns (CNHs) were synthesized a decade back, their applications in biomedical field are coming up very recently [115]. CNHs are considered a
bridge between carbon nanotubes (CNT) and fullerenes. They are one-dimensional
2
carbon nanostructure consisting of sp
carbon atoms. Because of the presence of
conical shape front tip CNHs are also known as nanocone [116]. They are structurally very similar to CNTs, the only difference is they are end capped by a cone
or horn. The cone angle is about 120°, length 40–50 nm, and diameter is 2–5 nm
(Fig. 8)[117, 118]. CNHs are frequently found to be in aggregates in different shapes
and morphology, e.g., dahlia flower like, bud like, seed like, etc. Among them, the
most prominent is dahlia like spherical structure having a diameter of 80–100 nm
[119, 120]. CNHs havevery different and unique properties which are absent in other
nanostructures. Because of their special beneficial properties, they are employed in
nano-oncology for delivery of anticancer drugs [121, 122]. A detailed study of the
application of covalent modified and non-covalent modified CNHs in cancer therapy
is available in article [116].
CNHs are synthesized by vaporizing some carbon material without any added
metal catalyst followed by quenching for removal of impurities [123]. Primarily three
methods are employed, e.g., arc discharge, laser ablation, and joule heating. Because
of the absence of metal impurities, the toxicity level in CNHs is much lower than that
of CNTs. This is the biggest advantage of CNHs for their biomedical applications
[124–126]. In addition to t his, CNHs have large surface area and high porosity. The
116 N. B. Singh et al.
Fig. 8 a Morphological representation of A Carbon Nanohorns with dahlia like structure and B
single CNH. Reproduced with permission from Elsevier [117], b TEM image CNH showing dahlia
like features. Reproduced with permission from Elsevier [118]
asymmetric structural features allow them easy loading and releasing of drugs either
through tip or walls [127]. CNHs can undergo covalent and non-covalent functional-
ization depending on whether more stable interactions or less stable interactions are
formed due to the formation or disruption of chemical bonds during their synthesis
Fig. 9 [116]. Covalent interactions involve attachment of organic molecule such as
polymeric materials on the surface to enhance biocompatibility and tailored properties. Non-covalent functionalization on CNHs includes π–π stacking interactions,
electrostatic interactions, packing bioactive molecules inside cavity, adsorbing metal
nanoparticles over the outer surface, etc. CNHs are more reactive than CNTs since
there is a loss of aromaticity due to the presence of many defect sites. Thus they
are prone to easy chemical modification. A lot of researches have been performed
on the ability of CHNs role as drug carrier to the site of tumor in cancer treatment.
In most cases of drug delivery by CHNs cisplatin is used as a chemotherapeutic
agent [128]. The efficacy of CHNs in drug delivery is enhanced with their NIR
absorption ability which recognizes their role in photothermal and photodynamic
therapy [129]. The heat generated during NIR irradiation kills the cancer cells in
photothermal process. However, in photodynamic process, cell death happens due to
the singlet oxygen and other reactive oxygen species. People have also explored the
conjugate role of photothermal with drug vector. For example, doxorubicine (DOX)
and cis platin were loaded on the surface of CNHs through π–π stacking interactions
of non-covalent functionalization along with suitable photo and chemotherapeutic
protocols for treatment of various cancer cells(Fig. 10)[128]. CHNs are also reported
for their biosensing applications. A glucose biosensor is fabricated by encapsulating
glucose oxidase in the Nafion-CNH composite [130]. Polysodium styrene sulfonate
functionalized CNHs can adsorb myoglobin and can act as an effective biosensor for
the detection of H
[131]. A recent report investigated the simultaneous determi-
2O2
nation of dopamine, uric acid, and ascorbic acid using CNH modified glassy carbon
electrode [132].
Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future … 117
Fig. 9 Various routes of functionalization in CNHs. Adapted and modified with permission from
[116]
Fig. 10 Scheme for preparation of Cisplatin and Doxorubicin loaded SW-Carbon Nanohorns.
Reproduced from Ivyspring International open [128]
118 N. B. Singh et al.
3.7 Fullerene in Drug Delivery
Fullerenes are clusters of carbon represented by Cn(n > 20) with a spherical surface.
2
All carbon atoms are sp
hybridized and form pentagons and hexagons by covalent
bonding with each carbon atom on the surface. Fullerenes are associated with some
interesting physical and chemical properties beneficial for drug delivery. Research
findings reported that fullerenes are highly compatible with the biomolecules. Thus
fullerene is considered a promising carbon-based nanomaterial in biomedical field
[133–137]. However, toxicity and high drug loading are the key limitations of this
material for its full utility. Several strategies are applied to overcome these issues
such as stabilization and functionalization.
The delivery of drug docetaxel is studied using functionalized fullerene (C
60
Higher apoptosis rate and antitumor efficacy was observed in case of functionalized
fullerene-docetaxel than that of free drug [138]. Controlled drug release systems
using functionalized fullerene were prepared as nano-vesicles. Various drugs such as
cisplatin, 5-fluorouracil cyclophosphamide, etc., are carried by these nano-vesicles
for release in a controlled delayed manner [139]. In the research by Wang et al. the
solubility of fullerene is improved by reacting with surfactant CTAF with magnetic
property. It is further modified by introducing DNA to hold anticancer drug DOX
[140]. Then C
@CTAB/DNA system is coated with HA-SS-COOH for controlling
60
agglomeration and to improve the morphology. It has been observed that cleavage of
disulphide bonds of glutathione significantly reduced the extratumoral environment
and encouraged the delivery of drug at the specific site. Glycine functionalized C
is reported for delayed drug delivery. Misra et al. have investigated drug delivery
of glycinated C
-fullerene conjugated with N-desmethyl tamoxifen and observed
60
higher drug loading and drug retaining efficacy [141]. Similarly, cancer drug DOX
conjugated with fullerene using a thioketal linking group for controlled drug delivery
application. This system exhibits better therapeutic effect, less toxicity, and slowdrug
release property [142, 143]. Some significant applications of fullerene in recent drug
delivery systems are listed in Table 6 highlighting its promising future in this field.
).
60
4 Challenges and Future Perspective
As discussed in this chapter, it is clear that in the past few years, carbon-based
nanomaterials (CBNs) are creating a lot of interest in drug delivery and biomedical
field [16, 17]. CBNs are equipped with remarkable optical, mechanical, and chemical
properties. The unique properties at the nanoscale alter their behavior inside the
body. Despite the long list of advantages, the CBNs have a number of limitations.
Scaling up the synthesis of CBNs to the industrial scale is not up to the mark.
Most of the CBNs face serious challenges while large scale production [15]. A
thorough understanding is required to devicean optimum methodology to tackle these
issues. The synthesis methodology must be economical, environment friendly and
Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future … 119
Tabl e 6 Some recent drug delivery applications of Fullerene. Adapted and reproduced with
permission from MDPI [1]
Drug used Method Functionalization Research inference
Ibuprofen Conjugation Transition metal N4
Hydroxyurea Conjugation Pristine C60,BC59,SiC59,
Doxorubicin Complexation Tolu ene Drug delivery to
Doxorubicin Complexation Tolu ene Function as
Choloroquine Chemical bonding Pristine C60and
N-desmethyl
tamoxifen
Reaction with glycine N-desmethyl tamoxifen
clusters
AlC
,
59
chloroquine
and glycine
Delivery of
ibuprofen
Hetero-fullerene for
drug delivery
cancer cells
photosensitizer
Al and Si doped
fullerene as drug
delivery vehicle
Controlled drug
release
produce high yield. Moreover,the toxicity issue of CBNs is one of the most important
challenges that need special attention [25]. Generation of toxic by-products to cause
health and environmental issues need stringent regulatory protocols during synthesis
and commercialization of CBNs. The poor aqueous solubility is another limitation
of CBNs application in drug delivery. Utilization of high end surface engineering
technology, these CBNs can be made biocompatible along with water solubility
which is a highly desirable property in drug delivery and tissue engineering field
[43]. Long term fate of the CBNs needs careful assessment to bring them further for
clinical trials to treat serious ailments. Thus the compatibility, safety, and efficacy of
CBNs are of prime importance to work on for their promising future applications in
drug delivery and clinical field.
5 Conclusions
The present chapter highlights the different roles and functions of CBNs in drug
delivery and biomedical applications. Throughout history, drug delivery has evolved
from traditional formulations to sophisticated nanomaterial-based strategies, and
CBNs have emerged as promising candidates for revolutionizing this domain. By
examining the historical journey, current breakthroughs, and promising prospects,
this chapter paves the way for harnessing the power of carbon-based nanomaterials
to users in a new era of precision medicine and improved patient outcomes. Use of
a number of carbon nanomaterials in medical sector with their positive and negative
impacts have been discussed in this chapter.
120 N. B. Singh et al.
Acknowledgements The authors are thankful to the management of Sharda University for
providing facilities and resources to conduct the present study.
Conflict of Interest The author declared no potential conflicts of interest with respect to the
research, authorship, and publication of this article.
References
1. Mehta VN, Raval JB, Kailasa SK, Rohit JV, Prajapati VS (2023) Application of functionalized carbon nanomaterials in therapeutic formulations. Chapter 3, in Book: Functionalized
carbon nanomaterials for theranostic applications. Mallakpour S, Hussain CM (eds), pp 55–74,
Elsevier
2. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’Regan RM (2006) Emerging use of
nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 8: 657–667
3. Wu X, Yang H, Yang W, Chen X, Gao J, Gong X, Wang H, Duan Y, Wei D, C hang J (2019)
Nanoparticle-based diagnostic and therapeutic systems for brain tumors. J Mater Chem B
7(31):4734–4750
4. Kedi PBE, Meva FE, Maaza M (2018) Eco-friendly synthesis, characterization, in vitro
and in vivo anti-inflammatory activity of silver nanoparticle-mediated Selaginella myosurus
aqueous extract. Int J Nanomedicine 13:8537–8548
5. Magro M, Venerando A, Macone A, Canettieri G, Agostinelli E, Vianello F (2020)
Nanotechnology-based strategies to develop new anticancer therapies. Biomol. Ther. 10(5):1–
25
6. Ruiu A, González-Méndez I, Sorroza-Martínez K, Rivera E (2023) Drug delivery aspects of
carbon nanotubes. Emerg Appl Carbon Nanotubes Drug Gene Delivery 119–155
7. Malik N, WiwattanapatapeeR, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus
W, Duncan R (2000) Dendrimers: relationship between structure and biocompatibility in vitro,
and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers
in vivo. J. Contr. Release 65:133–148
8. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future
prospects. Faseb J 19:311–330
9. Mignani S, Rodrigues J, TomasH,Roy R, Shi X, Majoral JP (2018) Dendrimers in combination
with natural products and analogues as anti-cancer agents. Adv Drug Deliv Rev 136–137:73–
81
10. Chirag M, Gowda DV, Babu S, Famna Roohi NK (2020) A Comprehensive review on
Dendrimers in current advanced Drug delivery. Int J Res Pharm Sci 11:1055–1066
11. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Sci 303:1818–
1822
12. Gopikrishna P, Meher N, Iyer PK (2018) Functional 1,8-Naphthalimide AIE/AIEEgens:
Recent Advances and Prospects. ACS Appl Mater Interfaces 10:12081–12111
13. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK (2012) Drug
delivery systems: an updated review. Int. J. Pharm. Invest. 2(1):2–11
14. Pal D, Nayak A (2015) Alginates, blends and microspheres: controlled drug delivery. In:
Mishra M (Ed), Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, Taylor &
Francis Group, New York 89–98
15. Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress,
challenges and opportunities. Nat Rev Cancer 17:20–37
16. Sultana A, Zare M, Thomas V, Kumar TSS, Ramakrishna S (2022) Nano-based drug delivery
systems: Conventional drug delivery routes, recent developments and future prospects. Med.
Drug Discov. 15:100134
Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future … 121
17. Kamel AA (2020) Carbon nanomaterials: 30 years of research in agro ecosystems. Carbon
Nanomaterials for Agri-food and Environmental Applications. Elsevier
18. Maiti D, Tong X, Mou X, Yang K (2019) Carbon-Based Nanomaterials for Biomedical
Applications. A Recent Study, Front Pharmacol 9:1401
19. Smalley RE (1997) Discovering the fullerenes. Rev Mod Phys 69(3):723
20. Smalley RE (1997) Discovering the fullerenes (Nobel lecture). Angew Chem Int Ed Engl
36(15):1594–1601
21. Iijima S (1991) Helical microtubules of graphitic carbon. Nature 354:56–58
22. Gaur M, Misra C, YadavAB, Swaroop S, Maolmhuaidh FÓ, Bechelany M, Barhoum A (2021)
Biomedical Applications of Carbon Nanomaterials: Fullerenes, Quantum Dots, Nanotubes,
Nanofibers, and Graphene. Materials 14(20):5978
23. Bandlapalli C, Gaddam HUS, Chintmaneni PK, Sudhan SHH, Hadipatri R (2021) Carbon
Nanoparticles: A Complete Review on Origin and Medical Application. Saudi J. Med. Pharm.
Sci. 7(8):395–410
24. Bayda S, Hadla M, Palazzolo S, Kumar V, Caligiuri I, Ambrosi E, Pontoglio E, Agostini M,
Tuccinardi T, Benedetti A (2017) Bottom-up synthesis of carbon nanoparticles with higher
doxorubicin efficacy. J Control Release 248:1–152
25. Peng Z, Liu X, Zhang W, Zeng Z, Liu Z, Zhang C, Liu Y, Shao B, Liang Q, Tang W, Yuan
X (2020) Advances in the application, toxicity and degradation of Carbon Nanomaterials in
environment: A review. Environ Int 134:105298
26. Devi KB, Garalleh HA, Alalawi A, Al-Sarayreh E, Pugazhendhi A (2023) Carbon nanomaterials: Types, synthesis strategies and their application as drug delivery system for cancer
therapy. Biochem Eng J 192:108–828
27. Darroudi M, Nazari SE, Kesharwani P,Rezayi M, Khazaei M, Sahebkar A (2023) Background
of carbon nanotubes for drug deliverysystems. (Chapter-1), Emerging Applications of Carbon
Nanotubes in Drug and Gene Delivery, pp 1–35, Woodhead Publishing
28. Goenka S, Sant V, Sant S (2014) Graphene-based nanomaterials for drug delivery and tissue
engineering. J Control Release 173:75–88
29. Chakraborty M, Hashmi MSJ (2018) Graphene as a Material – An Overview of Its Properties
and Characteristics and Development Potential for Practical Applications. Reference Module
in Materials Science and Materials Engineering 8:10319–10324
30. Debnath SK, Srivastava R (2021) Drug Delivery with Carbon-Based Nanomaterials as
Versatile Nanocarriers Progress and Prospects. Front. Nanotechnol. 3 1 22
31. Mahor A, Singh PP, Bharadwaj P, Sharma N, Yadav S, Rosenholm JM, Bansal KK (2021)
Carbon-Based Nanomaterials for Delivery of Biologicals and Therapeutics: A Cutting-Edge
Technology. C. J. Carb. Res. 7(1):19
32. Pattnaik S, Surendra Y, Rao JV, Swain K (2020) Carbon family nanomaterials for drug delivery
applications. Nanoeng. Biomat. Adv. Drug Deliv. 18:421–425
33. Priyadarsini S, Mohanty S, Mukherjee S, Basu S, Mishra M (2018) Graphene and graphene
oxide as nanomaterials for medicine and biology application. J. Nanostruc. Chem. 8:123–137
34. Liu Z, Robinson JT, Sun X, Dai H (2008) PEGylated nanographene oxide for delivery of
water-insoluble cancer drugs. J Am Chem Soc 130:10876–10877
35. Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, Dai H (2008) Nano-graphene
oxide for cellular imaging and drug delivery. Nano Res 1:203–212
36. Itoo M, Vemula SL, Gupta MT, Giram MV, Kumar SA, Ghosh B, Biswas S (2022) Multifunctional graphene oxide nanoparticles for drug delivery in cancer. J Control Release
350:26–59
37. Saharan R, Paliwal SK, Tiwari A, Tiwari V, Singh R, Beniwal SK, Dahiya P, Sagadevan S
(2023) Exploring graphene and its potential in delivery of drugs and biomolecules. J. Drug
Deliv. Sci. Technol. 84:1046
38. Moghadam NB, Avatefi M, Karimi M, Mahmoudifard M (2023) Graphene family in cancer
therapy: recent progress in cancer gene/drug deliveryapplications. J Mater Chem B 11:2568–
2613
122 N. B. Singh et al.
39. Liu J, Tao L, Yang W, Li D, Boyer C, Wuhrer R, Braet F, Davis TP (2010) Synthesis, characterization, and multilayer assembly of pH sensitive graphene-polymer nanocomposites.
Langmuir 26:10068–10075
40. Khakpour E, Salehi S, Naghib SM, Ghorbanzadeh S, Zhang W (2023) Graphene-based nanomaterials for stimuli-sensitive controlled delivery of therapeutic molecules. Front. Bioeng.
Biotechnol. 11:1–9
41. Kavitha T, Abdi SIH, Park S-Y (2013) PH-sensitive nanocargo based on smartpolymer
functionalized graphene oxide for site-specific drug delivery. Phys Chem Chem Phys
15:5176–5185
42. Boddu A, Obireddy SR, Zhang D, Rao KK, Lai W-F (2022) ROS-generating, pH-responsive
and highly tunable reduced graphene oxide-embedded microbeads showing intrinsic anticancer properties and multi-drug co-delivery capacity for combination cancer therapy. Drug
Deliv 29:2481–2490
43. Pooresmaeil M, Namazi H (2021) Fabrication of a smart and biocompatible brush copolymer
decorated on magnetic graphene oxide hybrid nanostructure for drug delivery application.
Eur Polym J 142:110126
44. Kim DJ, Kim J, Lee HL, Lee S, Choi JS, Kim SJ, Jeong YI, Kang DH (2018) RedoxResponsiveNanocomposites Composed of Graphene Oxide and Chlorin e6 for Photodynamic
Treatment of Cholangiocarcinoma. Bull Korean Chem Soc 39:1073–1082
45. Wang X, Guo W, Li L, Yu F, Li J, Liu L, Fang B, Xia L (2021) Photothermally triggered
biomimetic drug delivery of Teriparatide via reduced graphene oxide loaded chitosanhydrogel
for osteoporotic bone regeneration. Chem Eng J 413:127413
46. XiongS,LuoJ,WangQ,LiZ,LiJ,LiuQ,GaoL,FangS,LiY,PanH,WangH,ZhangY,
Wang Q, Chen X, Chen T (2021) Targeted graphene oxide for drug delivery as a therapeutic
nano platform against Parkinson’s disease. Biomater Sci 9:1705
47. Wu J, Qin Z, Jiang X, Fang D, Lu Z, Zheng L, Zhao J (2022) ROS-responsive PPGF nanofiber
membrane as a drug delivery system for long-term drug release in attenuation of osteoarthritis.
npj Regen Med 7,66
48. Lu T, Nong Z, Wei L, Wei M, Li G, Wu N, Liu C, Tang B, Qin Q, Li X, Meng F (2020)
Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide
drug delivery system. J Biomater Appl 35(1):15–27
49. Mihanfar A, Targhazeh N, Sadighparvar S, Darband SG, Majidinia M, Yousefi B (2021)
Doxorubicin loaded magnetism nanoparticles based on cyclodextrin dendritic-graphene oxide
inhibited MCF-7 cell proliferation. Biomol Concep 12:8–15
50. Borandeh S, Hosseinbeigi H, Abolmaali SS, Monajati M, Tamaddon AM (2021) Steric stabilization of β-cyclodextrin functionalized graphene oxide by host-guest chemistry: A versatile
supramolecule for dual-stimuli responsive cellular delivery of doxorubicin. J. Drug Deliv.Sci.
Technol. 63:102536
51. Karthika V, AlSalhi MS, Devanesan S, Gopinath K, Arumugam A, Govindarajan M (2020)
Chitosan overlaid Fe
/rGO nanocomposite for targeted drug delivery, imaging, and
3O4
biomedical applications. Sci Rep 10:1–17
52. Azhar FF,Rezaei M, Olad A, Mousazadeh H (2022) The effect of montmorillonite in graphene
oxide/chitosan nanocomposite on controlled release of gemcitabine. Polym Bull 79(8):5861–
5883
53. Wei X, Li P, Zhou H, Hu X, Liu D, Wu J, Wang Y (2021) Engineering of gemcitabine coated
nano-graphene oxide sheets for efficient near-infrared radiation mediated in vivo lung cancer
photothermal therapy. J Photochem Photobiol B Biol 216:112125
54. Yan J, Zhang Y, Zheng L, Wu Y, Wang T, Jiang T, Liu X, Peng D, Liu Y, Liu Z (2022) Let-7i
miRNA and platinum loaded nano-graphene oxide platform for detection/reversion of drug
resistance and synergetic chemical-photothermal inhibition of cancer cell. Chin Chem Lett
33(2):767–772
55. Zhang Z, Pan T, Zhao Y, Ren M, Li Y, Lu G, Wu K, He S (2021) Topotecan-loaded
thermosensitive nanocargo for tumor therapy: in vitro and in vivo analyses. Int J Pharm
606:120871
Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future … 123
56. Abdelhamid HN, Hussein KH (2021) Graphene oxide as a carrier for drug delivery of
methotrexate. Biointerface Res. Appl. Chem. 11:14726–14735
57. Wu Q, Qin M, Zhang K (2019) Synthesis of sevoflurane loaded reduced graphene oxidenanoparticles system for neuroprotective effects for preconditioning against focal cerebral
ischaemia. Artif. Cells. Nanomed. Biotechnol. 47:3517–3523
58. Priya PS, Vaishnavi S, Pavithra V, Pachaiappan R, Barathkumar S, Almutairi BO, Arokiyaraj
S, Arockiaraj J (2023) Graphene oxide decorated daidzein as an oral drug to ameliorate the
oxidative stress and glucocorticoid-induced osteoporosis in vivo zebrafish model. J. Drug.
Del. Sci. Technol. 81:104278
59. Henna TK, Pramod K (2020) Graphene quantum dots redefine nanobiomedicine. Mater Sci
Eng C 110:110651
60. Chung S, Revia RA, Zhang M (2019) Graphene Quantum Dots and Their Applications in
Bioimaging, Biosensing, and Therapy. Adv Mater 1904362:1–26
61. Prabhakar AK, Ajith MP, Ananthanarayanan A, Routh P, Mohan BC, Thamizhchelvan AM
(2022) Ball-milled graphene quantum dots for enhanced anti-cancer drug delivery.Open Nano
8:100072
62. Biswas MC, Islam MdT, Nandy PK, Hossain MdM (2021) Graphene quantum dots(GQDs)
for bioimaging and drug delivery applications: A review. ACS Mater. Lett. 3:889–911
63. Liu Y, Zhao C, Sabirsh A, Ye L, Wu X, Lu H, Liu J (2021) A Novel Graphene Quantum
Dot-Based mRNA Delivery Platform. Chem. Open 10:666–671
64. Felix DM, Alencar LMR, De Menezes FD, Midlej VDVP, Aguiar L, Piperni SG, Zhang J, Liu
Y, Ricci-Junior E, Alexis F, Junior SA, Zhu L, Santos-Oliveira R (2021) Graphene quantum
dots decorated with imatinib for leukemia treatment. J. Drug. Deliv. Sci. Technol. 61:102117
65. Lee G-Y, Lo P-Y, Cho E-C, Zheng J-H, Li M, Huang J-H, Lee K-C (2021) Integration of PEG
and PEI with graphenequantum dots to fabricate pH-responsive nanostars forcolon cancer
suppression in vitro and in vivo. Flat. Chem. 31:100320
66. Pooresmaeil M, Namazi H (2020) PH-sensitive ternary Fe
/GQDs@ G hybrid micro-
3O4
spheres; Synthesis, characterization and drug delivery application. J Alloy Compd 846:156419
67. Frieler M, Pho C, Lee BH, Dobrovolny H, Akkaraju GR, Naumov AV (2021) Effects
of doxorubicin delivery bynitrogen-doped graphene quantum dots on cancer cell growth:
experimental study and mathematical modelling. Nanomaterials 11(1):140
68. Ghafary SM, Rahimjazi E, Hamzehil H, Mousavi SMM, Nikkhah M, Hosseinkhani S (2022)
Design and preparation of a theranostic peptideticle for targeted cancer therapy:Peptide-based
codelivery of doxorubicin/curcumin and graphene quantum dots. Nanomedicine 42:1025
69. Yue J, He L, Tang Y, Yang L, Wu B, Ni J (2019) Facile design and development of photoluminescent graphene quantum dots grafted dextran/glycol-polymeric hydrogel for thermo
responsive triggered delivery of buprenorphine on pain management in tissue implantation. J
Photochem Photobiol B 197:111530
70. Sheng Y, Dai W, Gao J, Li H, Tan W, Wang J, Deng L, Kong Y (2020) PH-sensitive
drug delivery based on chitosan wrapped graphene quantum dots with enhanced fluorescent
stability. Mater Sci Eng C 112:110888
71. Nasrollahi F, Rui Y, Chen P, Varshosaz J, Ali A (2019) Targeting graphene quantum dots to
epidermal growth factor receptor for delivery of cisplatin and cellular imaging. Mater Sci Eng
C 94:247–257
72. Yu C, Long Z, Qui Q, Liu F, Xu Y, Zhang T, Guo R, Zhong W, Huang S, Chen S (2022)
Graphene quantum dots-based targeted nanoprobes detecting drug delivery, imaging, and
enhanced chemotherapy of nasopharyngeal carcinoma. Bioeng. Transl. Med. 7(2):e10270
73. Ghanbari N, Salehi Z, Khodadadi AA, Shokrgozar MA, Saboury AA, Farzaneh F (2021)
Tryptophan-functionalized graphene quantum dots with enhanced curcumin loading capacity
and pH-sensitive release. J. Drug. Deliv. Sci. Technol. 61:102137
74. Herlem G, Picaud F, Girardet C, Micheau O (2019) Carbon nanotubes: Synthesis, characterization, and applications in drug-delivery systems, nanocarriers for drug delivery, chapter 16,
Aa volume in Micro and Nano Technologies. Elsevier, 469–529
124 N. B. Singh et al.
75. Elhissi A, Ahmed W, Dhanak V, Subramani K (2012) Carbon Nanotubes in Cancer Therapy
and Drug Delivery. J Drug Deliv 1–10
76. Raval JP, Joshi P, Chejara DR (2018) Carbon nanotube for targeted drug delivery. Applications
of Nanocomposite Materials in Drug Delivery, chapter 9, Elsevier, 203–216
77. Lee W, Parpura V (2009) Carbon nanotubes as substrates/scaffolds for neural cell growth.
Prog Brain Res 180:111–125
78. Kharissova OV, Kharisov BI (2014) Variations of interlayer spacing in carbon nanotubes.
RSC Adv 4:30807–30815
79. M. Patila, N. Chalmpes, E. Dounousi, H. Stamatisa, D. Gournis, Use of functionalized
carbon nanotubes for the development of robust nanobiocatalysts. Methods in Enzymology,
chapter 12, Elsevier, 630, 263–301 (2020)
80. J. Kaur, G.S. Gill, K. Jeet, Applications of Carbon Nanotubes in Drug Delivery: A
Comprehensive Review, Charact. Biol. Nanomater. Drug Deliv. 113–135 (2019)
81. Dong X, Sun Z, Wang X, Zhu D, Liu L, Leng X (2017) Simultaneous monitoring of the drug
release and antitumor effect of anovel drug delivery system-MWCNTs/DOX/TC. Drug Deliv
24(1):143–151
82. Cao X, Tao L, Wen S, Hou W, Shi X (2015) Hyaluronic acid-modified multiwalled carbon
nanotubes for targeted delivery of doxorubicin into cancer cells. Carbohydr Res 405:70–77
83. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ (2008) Targeted Single-Wall Carbon NanotubeMediated Pt(IV) Prodrug Delivery Using Folate as a Homing Device. J Am Chem Soc
130:11467–11476
84. Madani SZM, Safaee MM, Gravely M, Silva C, Kennedy S, Bothun GD, Roxbury D (2021)
Carbon Nanotube-Liposome Complexes in Hydrogels for Controlled Drug Delivery via NearInfrared Laser Stimulation. ACS Appl. Nano. Mater. 4(1):331–342
85. A. Jagusiak, K. Chłopa´s,G.Zemanek,M.Jemioła-Rzemi´nska, B. Piekarska, B. Stopa,
Self-assembled supramolecular ribbon-like structures complexed to single walled carbon
nanotubes as possible anticancer drugdelivery systems. Int. J. Mol. Sci. 20, 2064 (2019)
86. H. Al Garalleh, A.Algarni, Modelling of paclitaxel conjugated withcarbon nanotubes as an
antitumor agent for cancer therapy. J. Biomed. Nanotechnol. 16, 224–234 (2020)
87. Zomorodbakhsh S, Abbasian Y, Naghinejad M, Sheikhpour M (2020) The effects study of
isoniazid conjugated multi-wall carbon nanotubes nano fluid on mycobacterium tuberculosis.
Int J Nanomed 15:5901–5909
88. Rathod V, Tripathi R, Joshi P, Jha PK, Bahadur P, Tiwari S (2019) Paclitaxel encapsulation
into dual-functionalized multi-walled carbon nanotubes. AAPS Pharm. Sci. Tech. 20:51
89. Chen K, Mitra S (2019) Incorporation of functionalized carbon nanotubesinto hydrophobic
drug crystals for enhancing aqueous dissolution. Colloids Surf B Biointer 173:386–391
90. Andersen CK, Khatri S, Hansen J, Slott S, Parvathaneni RP, Mendes AC, Chronakis
IS, Hung S-C, Rajasekaran N, Ma Z, Zhu S, Dai H, Mellins ED, Astakhova K (2021)
Carbon Nanotubes—Potent Carriers for Targeted Drug Delivery in Rheumatoid Arthritis.
Pharmaceutics 13(4):453
91. N. Bondon, L. Raehm, C. Charnay, R. Boukherroub, J. Durand O, Nanodiamonds for bio
applications, recent developments. J. Mater. Chem. B 8, 10878–10896 (2020)
92. Reina G, Orlanducci S, Cairone C, Tamburri E, Lenti S, Cianchetta I (2015) Rhodamine/
nanodiamond as a system model for drug carrier. J Nanosci Nanotechnol 15:1022–1029
93. Tinwala H, Wairkar S (2019) Production surface modification and biomedical applications of
nanodiamonds: a sparkling tool for theranostics. Mater Sci Eng C 97:913–931
94. M. Gu, T.B. Toh,L. Hooi, L. J, X. Zhang, and Chow,E. K. Nanodiamond-mediated delivery of
a G9a inhibitor for hepatocellular carcinoma therapy. ACS Appl. Mater. Inter. 11, 45427–451
(2019)
95. Turcheniuk K, Mochalin VN (2017) Biomedical applications of nanodiamond (Review).
Nanotechnology 28:252001
96. K.D. Patel, R.K. Singh H.W Kim, Carbon-based nanomaterials as an emerging platform for
theranostics. Mater. Horiz. 6, 434–469 (2019).